Human milk fat globule-EGF factor 8 (MFG-E8), also known as lactadherin, is a secreted glycoprotein that plays essential roles in the clearance of apoptotic cells and angiogenesis. It has been reported that serum MFG-E8 levels are higher in systemic lupus erythematosus (SLE) patients compared with in healthy controls; however, a previous study reported no correlation between serum MFG-E8 levels and SLE disease activity. The objective of this study was to assess serum MFG-E8 levels and their clinical associations in patients with SLE. Serum MFG-E8 levels in 49 Japanese patients with SLE, eight with cutaneous LE, and 28 healthy controls were examined. Serum MFG-E8 levels in SLE patients were significantly higher than those in cutaneous LE patients and healthy individuals. In addition, serum MFG-E8 levels were positively correlated with the SLE Disease Activity Index score, which reflects the disease activity of SLE. Notably, the frequency of the presence of high-intensity cerebral lesions on MRI in the SLE patients with elevated serum MFG-E8 levels was significantly higher than that in SLE patients with normal serum MFG-E8 levels. These findings suggest that elevated serum MFG-E8 levels may be associated with cerebrovascular diseases or neuropsychiatric SLE in patients with SLE, and that the measurement of serum MFG-E8 levels in SLE patients is useful for risk stratification of cerebrovascular disease or cerebrovascular diseaserelated neuropsychiatric SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with an autoantibody to nuclear component, such as antinucleolar and anti-dsDNA antibodies, and is caused by multiple genetic and environmental factors. 1 Patients with SLE develop various clinical manifestations in the skin, lung, kidney, nervous system, and cardiovascular and cerebrovascular systems. Apoptotic cells can be found in the germinal centers of lymph nodes of SLE patients, and macrophages from SLE patients showed impaired phagocytosis of apoptotic cells. 2 The persistence of apoptotic cells may induce secondary necrotic cell death, leading to inflammation and an autoimmune response. Thus, deficiencies in the clearance of apoptotic cells have been considered to be one of the causative factors of SLE. Human milk fat globule-EGF factor 8 (MFG-E8), also known as lactadherin, is a secreted glycoprotein with an Nterminal EGF-like domain and two C-terminal discoidin-like domains (C1 and C2) that share homology with the blood coagulation factors V and VIII. 3, 4 The EGF-like domain contains the integrin-binding RGD motif, which binds to integrin aVb3/5. 3,4 MFG-E8 is secreted by various cells, including macrophages, dendritic cells, endothelial cells and pericytes. [5] [6] [7] MFG-E8 plays essential roles in the clearance of apoptotic cells. Early apoptotic cells express phosphatidylserine (PS) on the surface as an "eat-me" signal, and MFG-E8 acts as a bridging protein between PS on apoptotic cells and integrin aVb3/5 on phagocytes, leading to the promotion of phagocytosis of apoptotic cells by phagocytes. 8 In addition, MFG-E8 knockout mice have been reported to develop an autoimmune phenotype resembling SLE, which is characterized by the appearance of antinuclear and anti-dsDNA antibodies and the deposition of immune complexes in the glomeruli and glomerulonephritis. [7] [8] [9] Furthermore, interactions of MFG-E8 with integrin aV have also been implicated in the regulation of various functions, such as angiogenesis and mammary gland branching. 5, 6, [10] [11] [12] [13] [14] With respect to SLE and MFG-E8, it has been reported that serum MFG-E8 levels are higher in SLE patients compared with in healthy controls. [15] [16] [17] A positive correlation between serum MFG-E8 levels and immune complex level was reported. 16 However, another study found no correlation between serum MFG-E8 levels and SLE disease activity. 17 In the present study, we analyzed the serum MFG-E8 levels in SLE and cutaneous LE patients and healthy individuals, associations of serum MFG-E8 levels with the disease activity of SLE, and demographic and clinical features of SLE patients with elevated serum MFG-E8 levels.
METHODS Patients
We analyzed 49 Japanese patients with SLE who visited Gunma University Hospital (44 female and five male; aged 47.6 AE 1.9 years). All of the patients fulfilled the criteria for SLE proposed by the Systemic Lupus International Collaborating Clinics. 18 In addition, eight Japanese patients with cutaneous LE (CLE) who had subacute CLE (SCLE), discoid LE (DLE) and LE profundus, but not SLE (five female and three male; aged 48.4 AE 6.1 years). Twenty-eight age-and sex-matched healthy Japanese individuals (26 female and two male; aged 55 AE 3.8 years) were used as healthy controls. This study was approved by the Institutional Review Board of Gunma University (#1441). The patients provided written informed consent before participation.
Clinical and laboratory assessments
Disease activity of SLE was assessed by SLE Disease Activity Index (SLEDAI). 19 Cerebral lesions were assessed by magnetic resonance imaging (MRI) of the head. Serum MFG-E8 levels were quantified via a Quantikine ELISA kit according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
Statistics
The Mann-Whitney U-test or ANOVA followed by Bonferroni's post-hoc tests were used for comparisons. v 2 -Test analysis was used to compare frequencies. Spearman's rank correlation coefficients were used to examine the correlation with serum MFG-E8 levels and SLEDAI. The error bars represent the standard errors of the means.
RESULTS
Serum MFG-E8 levels in SLE patients were significantly higher than those in CLE patients and healthy individuals It has been reported that serum MFG-E8 levels in SLE are elevated compared with in healthy controls. [15] [16] [17] In the present study, serum MFG-E8 levels of SLE patients were significantly higher than those of CLE patients and healthy individuals (SLE 1000.6 AE 82.6 pg/mL vs CLE 682 AE 57.6 pg/mL vs healthy individuals 790.2 AE 38.8 pg/mL) ( Fig. 1 ). Serum MFG-E8 levels in CLE patients were comparable with those in healthy individuals ( Fig. 1 ). These results suggest that elevated serum MFG-E8 is associated with SLE.
Serum MFG-E8 levels were positively correlated with disease activity in SLE patients
Only one study has reported that there is no correlation between serum MFG-E8 levels and SLE disease activity. 17 We also analyzed the relationship between serum MFG-E8 levels and SLE disease activity by determining SLEDAI scores. We found that serum MFG-E8 levels were positively correlated with SLEDAI (P < 0.01, Fig. 2 ). However, because the r-value was 0.3805, the association was weak. These results suggest that serum MFG-E8 levels may be associated with disease activity in SLE patients.
Demographic and clinical features of SLE patients with and without elevated serum homocysteine levels
The demographic and clinical features of SLE patients with and without elevated serum MFG-E8 levels are summarized in Table 1 . Elevated levels were defined as values higher than the mean + 2 standard deviations (1200.8 pg/mL) of the serum samples from healthy controls. We identified 11 SLE patients with elevated serum MFG-E8 levels (22.4%; mean age, 49.6 years) and 38 SLE patients with normal serum MFG-E8 levels (77.6%; mean age, 46.9 years). The SLEDAI was significantly higher in SLE patients with elevated serum MFG-E8 levels (11 vs 6.6, P < 0.05). However, the frequency of typical symptoms of SLE, such as fever, arthritis, malar rush, oral ulcer, alopecia, DLE and renal dysfunction, was comparable between the two groups (Table 1) . Notably, the frequency of the presence of high-intensity cerebral lesions on MRI in SLE patients with elevated serum MFG-E8 levels was significantly higher than that in SLE patients with normal serum MFG-E8 levels (72.7% vs 38.2%, P < 0.05). Among 21 SLE patients with high-intensity cerebral lesions on MRI, 38.1% (8/21) of patients had high serum MFG-E8 levels. In contrast, 10.7% (3/ 28) of SLE patients without cerebral lesions on MRI had high serum MFG-E8 levels, indicating that the frequency of elevated serum MFG-E8 levels in SLE patients with high-intensity cerebral lesions on MRI was significantly higher than that in patients without cerebral lesions on MRI (P = 0.023).
Imaging findings by cerebral MRI in 11 SLE patients with elevated serum MFG-E8 levels are summarized in Table 2 . Eight of 11 SLE patients with elevated serum MFG-E8 levels showed abnormal cerebral lesions on MRI, including highintensity signals in white matter, cerebrum and cerebellum. Among eight SLE patients with high-intensity cerebral lesions on MRI, four cases had neurological symptoms, such as psychosis, epilepsy, hemiplegia and muscle weakness in limbs caused by chronic inflammatory demyelinating polyneuropathy, but four cases had asymptomatic cerebral lesions on MRI (Table 2) .
No significant differences in the values of white blood cells, lymphocytes, platelets, complements and C-reactive protein (CRP), as well as the prevalence of autoantibodies, including antinuclear, anti-dsDNA, anti-RNP, anti-SM, anti-SSA and antib2 glycoprotein 1 antibodies and lupus anticoagulant were observed between the two groups. The frequencies of 
DISCUSSION
Three studies have reported that serum MFG-E8 levels are elevated in SLE patients compared with in healthy controls.
15-17
Yamaguchi et al. 15 reported that 17 of 172 adult SLE patients and 16 of 72 childhood-onset SLE patients had significantly high levels of serum MFG-E8, and medical treatment of these patients with high levels of serum MFG-E8 significantly lowered these levels and resulted in clinical improvement. Another study also reported that serum MFG-E8 levels were negative after treatment, but increased again upon relapse. 16 Lauber et al. 20 reported that mRNA levels of MFG-E8 were elevated in peripheral blood monocytes in patients with rheumatic diseases, including SLE. Yamaguchi et al. 15 examined the relationship between MFG-E8 levels and the extent of phagocytosis of apoptotic cells. The efficacy of phagocytosis of apoptotic cells showed a bell-shaped response to human MFG-E8, suggesting that excess MFG-E8 saturates the binding sites on apoptotic cells and phagocytes, and thus cannot function as a bridging protein, leading to impaired apoptotic cell clearance. They also suggested that an excess or complete loss of MFG-E8 is associated with the pathogenesis of SLE. 15 Consistent with the previous results, we found that serum MFG-E8 levels in SLE patients were significantly higher than those in CLE patients and healthy individuals. However, no studies have assessed serum MFG-E8 levels in CLE patients. Yamamoto et al. 16 reported a positive correlation between serum MFG-E8 levels and immune complex level, and tumor necrosis factor-a, c-interferon and interleukin-10 were significantly higher in MFG-E8-elevated SLE patients. Madkour et al. 17 reported a positive correlation between serum MFG-E8 levels and proteinuria; however, there was no correlation between serum MFG-E8 levels and SLE disease activity. In our study, clinical manifestations, including fever, arthritis, skin and renal lesions, laboratory findings, including blood cells counts, complement (CH50, C3, C4) and C-reactive protein, and the positivity of autoantibodies, were comparable between SLE patients with and without elevated serum MFG-E8. However, we found that serum MFG-E8 levels were positively correlated with SLEDAI, and that the frequency of the presence of highintensity cerebral lesions on MRI was significantly higher in SLE patients with elevated serum MFG-E8 levels. In addition, the frequency of elevated serum MFG-E8 levels was significantly higher in SLE patients with abnormal cerebral lesions on MRI. These results suggest that elevated serum MFG-E8 levels may be associated with cerebrovascular diseases in SLE. As SLEDAI includes the development of cerebrovascular disorder, elevated SLEDAI in SLE patients with elevated serum MFG-E8 levels may be related to the high frequency of the presence of high-intensity cerebral lesions on MRI (72.7%, 8/11). Neuropsychiatric systemic lupus erythematosus (NPSLE) includes the neurological syndromes of the central, peripheral and autonomic nervous system, and the psychiatric syndromes observed in patients with SLE. 21, 22 The term "central nervous system lupus" is included in NPSLE. The American College of Rheumatology established nomenclature and detailed case definitions for 19 neuropsychiatric syndromes in SLE, and "cerebrovascular disease" was included within 19 neuropsychiatric syndromes. 21 MRI is the imaging technique of choice in the diagnosis of NPSLE. 22 It is widely available and permits identification of lesions associated with NPSLE. It has been reported that the abnormal lesions in brain MRI, such as hyperintensity in white matter, was sometimes detected in SLE patients. 23, 24 Jeong et al. 23 reported that 219 SLE patients were screened by brain MRI, and 60.7% (133/219) of SLE patients had brain MRI of NPSLE. It has also been reported that asymptomatic cerebral lesions on MRI are not rare in patients with SLE. 24 The most common MRI abnormality of NPSLE was hyperintensity in white matter (57.1%). 23 In Based on these criteria and findings, SLE patients with highintensity brain lesions on MRI in our study were suspected as having cerebrovascular diseases or cerebrovascular diseaserelated NPSLE. The pathogenesis of cerebrovascular diseases in SLE patients with elevated serum MFG-E8 levels is unknown. Interestingly, a recent study found that PS exposure on erythrocytes, platelets and leukocytes was significantly elevated in patients with acute ischemic stroke, and the addition of MFG-E8 to blood cells from acute ischemic stroke patients delayed coagulation time by approximately 20% and blocked the generation of blood coagulation factor Xa and thrombin by approximately 50%, 27 suggesting that MFG-E8 has therapeutic anticoagulation potential for ischemic cerebral infarction. Additionally, some reports using animal models of cerebral infarction showed that MFG-E8 deficiency resulted in a larger infarct size and that administration of MFG-E8 reduced infarct size. 28, 29 In addition, we previously determined that hypoxia stimulation enhanced the synthesis of MFG-E8 in vascular endothelial cells and pericytes in vivo and in vitro, and that MFG-E8 expression in the skin of mice with ischemiareperfusion injury was enhanced in vivo. 12, 13 Collectively, elevated serum MFG-E8 levels may play protective roles against cerebrovascular diseases, including ischemic cerebral infarction in patients with SLE. Finally, our results suggest that the measurement of serum MFG-E8 levels in SLE patients is useful for risk stratification of cerebrovascular diseases or cerebrovascular disease-related NPSLE. In addition, the measurement of serum MFG-E8 may be helpful in predicting asymptomatic cerebral lesions in patients with SLE. Further investigations are needed to clarify these issues. In addition, measurement of serum MFG-E8 levels in patients with cerebrovascular disorders other than SLE patients may provide us with new clinical data to understand the clinical significance of MFG-E8.
